Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Upifitamab Rilsodotin for Cancer
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is testing the safety of a new antibody-drug conjugate (ADC) called XMT-1536 in patients with various types of cancer. The ADC will be administered as an IV infusion every 4 weeks. This study will also assess the ADC's activity and how it is metabolized by the body.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.